Such MIS416 hyper-responsiveness may be due to NFκB gene and pathway mutations described in MS patients which are associated with higher constitutive NFκB activity and greater sensitivity to NFκB-activating agents [44, 45]. Here, NFKB1 is linked to myeloid sarcoma.